CONGRESS|#EHA2021|@ThierryFacon, presented OS rate from Phase 3 MAIA clinical trial for D-Rd vs Rd alone in pts with NDMM who are transplant ineligible. Results indicated 32% reduction in risk of death #mmsm, #myeloma, Lille University Hospital pic.twitter.com/aAbuP3j9rD
— Multiple Myeloma Hub (@MM_Hub) June 12, 2021